Features
Get A Demo
Plans
Sign Up
Login
All Federal Contract IDV Awards
Help
Indefinite Delivery Contract HHSN271201700008I
Award Date
3/31/17
Last Date to Order
3/31/24
Overview
🤔 AI Insights
Buyer Personas
Industry Personas
Buyer Personas In this Market
Activity
Contract IDVs
Contract Awards
1
Transactions
6
Price Lists
Opportunity Stack
1
Funding Federal Agency
National Center for Advancing Translational Sciences
Contracting Federal Agency
National Institute on Drug Abuse
Awardee
Regents Of The University Of Minnesota
Ultimate Awardee
Not listed
NAICS Category
325411 - Medicinal and Botanical Manufacturing
PSC Category
AN11 - Health R&D Services; Health Care Services; Basic Research
Set-Aside Type
No Set-Aside Used
Federal Contract Vehicle
CRO Support for NCATS Drug Substance Development and Manufacture
Pricing Type
Order Dependent (IDV only)
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
CRO Support for NCATS Drug Substance Development and Manufacture
Master IDIQ
HHSN271201700008I
Indefinite Delivery Contract
1
Federal Contract Awards
Description
Update #1
Update #2
Update #3
PARENT IDIQ AWARD: CRO SUPPORT FOR NCATS DRUG SUBSTANCE DEVELOPMENT AND MANUFACTURE
Posted 3/31/17, 12:00 AM
Mod #
Description
Reason For Modification
Federal Obligation
(Click to sort descending)
Date
(Click to sort ascending)
P00005
PARENT IDIQ AWARD: CRO SUPPORT FOR NCATS DRUG SUBSTANCE DEVELOPMENT AND MANUFACTURE
Other Administrative Action
$0
6/13/22
P00004
PARENT IDIQ AWARD: CRO SUPPORT FOR NCATS DRUG SUBSTANCE DEVELOPMENT AND MANUFACTURE
Other Administrative Action
$0
3/29/22
P00003
EO 14042 - PARENT IDIQ AWARD: CRO SUPPORT FOR NCATS DRUG SUBSTANCE DEVELOPMENT AND MANUFACTURE EDITED BY PLUGGERN_NIH ON 10/22/2021 19:09:22
Funding Only Action
($5k)
2/18/22
P00002
EO14042 - PARENT IDIQ AWARD: CRO SUPPORT FOR NCATS DRUG SUBSTANCE DEVELOPMENT AND MANUFACTURE EDITED BY PLUGGERN_NIH ON 10/22/2021 19:09:22
Supplemental Agreement for work within scope
$0
10/22/21
1
PARENT IDIQ AWARD: CRO SUPPORT FOR NCATS DRUG SUBSTANCE DEVELOPMENT AND MANUFACTURE
Funding Only Action
$0
9/17/18
Name
Description
Awardee
Potential Value
(Click to sort descending)
Award Date
(Click to sort descending)
Completion Date
(Click to sort descending)
Updated At
(Click to sort descending)
Delivery Order HHSN271201700008I-75N95020F00001
This federal contract award to the Regents of the University of Minnesota, a major public research university, is for extended Chemistry, Manufacturing, and Controls (CMC) studies in support of the development of 2R,6R-HNK. The contract has a ceiling value of $1,243,134.81 and is a delivery order under the National Center for Advancing Translational Sciences' (NCATS) broader Contract Research Organization (CRO) Support for Drug Substance Development and Manufacture vehicle. The work will be performed in Minneapolis, Minnesota, and does not have a set-aside designation. As a leading research institution, the University of Minnesota has considerable experience providing specialized R&D services to federal agencies across diverse scientific domains, including biomedical research, engineering, and agricultural studies.
Regents Of The University Of Minnesota
$1.2m
9/18/20
5/31/26
11/20/24
Name
Description
Solicitation Number
Federal Agency
Type
Posted Date
(Click to sort descending)
CRO Support for NCATS Drug Substance Development and Manufacture
Added: Mar 01, 2016 11:41 am This is not a Request for Proposals (RFP). This is a Pre-solicitation Announcement only. RFP No. N01TR-17-2001, titled "CRO Support for NCATS Drug Substance Development and Manufacture," will be issued via fedbizopps on or about March 17, 2016.The Division of Preclinical Innovation (DPI) at the National Center for Advancing Translational Sciences (NCATS) conducts translational research in the area of human therapeutics development and aims to move small molecule and biologic drug candidates forward in the drug development pipeline, at which point, DPI will hand off the drug candidate to external partner(s) to bring the novel therapy to patients.The overall goal of this proposed project is to support the DPI drug development program by contracting for Chemistry, Manufacturing, and Control services. Specifically, this proposed project is designed to ensure DPI receives Active Pharmaceutical Ingredients and formulated Drug Product of sufficient quality and quantity to support IND-enabling, pre-clinical, and clinical studies.To accomplish this goal, the Government plans to solicit proposals from offerors having in-house capability in one or more of the following technical areas: (1) Manufacture and Analysis of Small Molecules; (2) Manufacture and Analysis of Synthetic Peptides, Oligonucleotides, and Related Substances; and (3) Manufacture and Analysis of Biopharmaceuticals.The Government anticipates awarding multiple Indefinite Delivery/Indefinite Quantity (IDIQ) type contracts under this solicitation.The ultimate goal of DPI and this planned project is to bring new drugs to market. To this end, the Government will seek a Determination of Exceptional Circumstances (DEC) to deviate from the Federal Acquisition Regulation clauses at 52.227-11 Patent Rights and 52.227-14 Rights in Data. The deviated language will enable DPI contributors to retain control of their intellectual property, will be included in the RFP, and incorporated in any resultant contract. Prospective Offerors are advised that agreement to the terms of these FAR clauses deviations will be a condition for contract award.Based upon market research, the Government is not using the policies contained in Part 12, Acquisition of Commercial Items, in its solicitation for the described supplies or services. However, interested persons may identify to the Contracting Officer their interest and capability to satisfy the Government's requirement with a commercial item within 15 days of this notice.
N01TR-17-2001
Department of Health and Human Services National Institutes of Health
Award Notice 1/1
3/1/16, 11:41 AM